ASCO 2014: Clovis, AstraZeneca face off with EGFR, PARP inhibitors
This article was originally published in Scrip
Executive Summary
Clovis Oncology and AstraZeneca are showing data for two sets of competing drugs at the 50th Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago, kicking off the first full day of abstract presentations with updated clinical trial results for Clovis's CO-1686 and rucaparib and AstraZeneca's AZD9291 and olaparib.